{"data":{"type":"company_profile_ai","id":63072,"entity_id":"wefunder:company:63072","attributes":{"canonical_url":"https://wefunder.com/osnovum","retrieval_urls":{"canonical":"https://wefunder.com/osnovum","json":"https://wefunder.com/osnovum.json","markdown":"https://wefunder.com/osnovum.md","ai_json":"https://wefunder.com/osnovum.ai.json","ai_text":"https://wefunder.com/osnovum.ai.txt","changelog_json":"https://wefunder.com/osnovum.changelog.json","schema":"https://wefunder.com/.well-known/ai-profile-schema.json"},"updated_at":"2026-06-04T05:02:21Z","generated_at":"2026-06-04T15:19:25Z","profile_visibility":{"owner_published":true,"public_search_results":true,"site_search_listed":true,"privacy_mode":"promote","invite_only":false},"company":{"id":63072,"entity_id":"wefunder:company:63072","slug":"osnovum","name":"OsNovum","tagline":"Revolutionizing the $25B osteoporosis industry with a novel regenerative solution for weak bones","elevator_pitch":"OsNovum has developed the technology to regenerate bone to maintain skeletal health. Weak bones are a major reason for frailty as we age. OsNovum has the proven technology to regenerate bone but will also open clinics devoted exclusively to skeletal heath and the prevention of frailty as we age.","location":"Henderson, NV","website":"https://www.OsNovum.com","total_amount_raised":383626,"total_investors":230,"is_funded":true,"is_active":true},"key_claims":[{"claim_id":"claim-total-raised","text":"Total raised on Wefunder: 383626","citation":"https://wefunder.com/osnovum#claim-total-raised","provenance":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-04T05:02:21Z","as_of":"2026-06-04T15:19:25Z","confidence":"high"},"observed_at":"2026-06-04T05:02:21Z","expires_at":"2026-06-05T05:02:21Z"},{"claim_id":"claim-total-investors","text":"Total investors: 230","citation":"https://wefunder.com/osnovum#claim-total-investors","provenance":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-04T05:02:21Z","as_of":"2026-06-04T15:19:25Z","confidence":"high"},"observed_at":"2026-06-04T05:02:21Z","expires_at":"2026-06-05T05:02:21Z"}],"verified_facts":[{"claim_id":"claim-total-raised","text":"Total raised on Wefunder: 383626","citation":"https://wefunder.com/osnovum#claim-total-raised","provenance":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-04T05:02:21Z","as_of":"2026-06-04T15:19:25Z","confidence":"high"},"observed_at":"2026-06-04T05:02:21Z","expires_at":"2026-06-05T05:02:21Z"},{"claim_id":"claim-total-investors","text":"Total investors: 230","citation":"https://wefunder.com/osnovum#claim-total-investors","provenance":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-04T05:02:21Z","as_of":"2026-06-04T15:19:25Z","confidence":"high"},"observed_at":"2026-06-04T05:02:21Z","expires_at":"2026-06-05T05:02:21Z"}],"company_claims":{"tagline":"Revolutionizing the $25B osteoporosis industry with a novel regenerative solution for weak bones","elevator_pitch":"OsNovum has developed the technology to regenerate bone to maintain skeletal health. Weak bones are a major reason for frailty as we age. OsNovum has the proven technology to regenerate bone but will also open clinics devoted exclusively to skeletal heath and the prevention of frailty as we age.","story":"At OsNovum, we are pioneering a breakthrough solution for osteoporosis and osteopenia—conditions that silently rob millions of their mobility, independence, and quality of life. Our mission is simple but powerful: to transform bone health through innovative regenerative technology and deliver lasting hope for those suffering from these debilitating diseases.Osteoporosis, often called the \"silent thief,\" affects over 200 million people worldwide and causes 8.9 million fractures annually. Current treatments come with severe side effects, leaving patients with limited and often difficult decisions to make. We believe they deserve better.Building on decades of research, our FDA-cleared technology goes beyond treating symptoms—it regenerates poorly mineralized bone, transforming it into dense, healthy vital bone. Our patented molecule works by targeting the patient’s own bone-growing cells (osteoblasts), stimulating natural regeneration without the risks of systemic side effects.Localized Application: Our regenerative material is applied locally to areas of low bone density, ensuring targeted and efficient treatment.Natural Bone Regeneration: The patient’s osteoblasts absorb our patented compound, migrate into surrounding tissue, and rebuild bone with increased mineral density and vitality.A New Standard of Care: Our long-term goal is to establish specialized clinics where patients can access skeletal treatments based on the latest scientific knowledge and advancements in bone health. \u0026nbsp;The global osteoporosis market is projected to reach $25.3 billion by 2025, presenting a major opportunity for disruptive innovation. OsNovum is uniquely positioned to capture market share by offering a novel, science-based solution to an underserved population. We plan to launch in key U.S. markets and strategically expand to meet international demand.Our maxillofacial technology has already been FDA-cleared and successfully used to regenerate maxillofacial bone in thousands of patients over the past decade. We are now adapting this proven technology for skeletal applications. With regulatory experts and strategic partners on board, we’re on track to submit a De Novo application—an essential milestone on our path to market entry.At OsNovum, our team includes seasoned industry leaders, including a former FDA assistant director and world-class scientists, who bring decades of experience in biotechnology and regulatory compliance. This expertise ensures that every step of our journey—research, development, and market entry—is executed with precision and strategy.We are committed to transforming bone health. Your investment can help accelerate the delivery of this groundbreaking solution to millions of patients in need. Together, we can reshape the future of osteoporosis care.Invest in OsNovum and be part of the next major breakthrough in healthcare innovation. With our proven regenerative technology and a clear path to FDA approval, we’re on the brink of revolutionizing osteoporosis care.Help us create a future where bone loss is no longer a life-altering diagnosis. Join us in turning innovation into impact and redefining the standard of care in bone health.From Dental Success to Skeletal InnovationIn 2016, SteinerBio began adapting its proven regenerative technology—originally FDA-cleared for maxillofacial applications—to treat failing skeletal bone. While this material had successfully restored bone health in thousands of dental patients, applying it to the skeleton required a separate regulatory pathway. Thus, OsNovum was born to pioneer this transition and bring our innovative bone regeneration technology to patients suffering from osteoporosis and other skeletal diseases.Regulatory Journey: Navigating Uncharted TerritoryWe initially pursued a 510(k) application, using SteinerBio’s FDA-cleared regenerative material as predicate technology. However, the FDA’s Skeletal Device division had never encountered a device that actively stimulates bone growth. As a result, they were navigating uncharted regulatory territory and ultimately ruled out the 510(k) option.The core issue: the Skeletal Device division does not recognize maxillofacial materials as predicates for skeletal use. With a PMA submission ruled out due to impracticality, we found the optimal path forward: De Novo submission.Why De Novo?De Novo submissions are designed for unique devices that present moderate risk and have no prior classification history. OsNovum’s technology fits these criteria perfectly. Shortly after receiving our Q-submission response from the FDA, we were approached by a former FDA principal who had worked on our original submissions. Now a consultant, this expert offered to help guide our De Novo application. Contracting their consulting firm was a monumental step in advancing our regulatory process.Next Steps: Securing Clearance and FundingTo succeed with our De Novo application, we need to raise funds to cover critical expenses:$30,000 FDA submission fee for the De Novo requestConsulting fees for experts guiding us through the processAdditional laboratory testing beyond what we've already completed, if required by the FDAWith this team and plan in place, we’re optimistic about achieving clearance without requiring human clinical trials. However, we know that the FDA never grants approval without demanding thorough validation.Forward Momentum: Moving Full Speed AheadRegardless of the challenges or amount raised, OsNovum remains committed to moving forward at full speed. Our mission to revolutionize bone health is too important to slow down. Together, we can create a future where skeletal diseases are treated with precision, innovation, and success.","quick_facts":["Patented bone-regenerating technology ready to disrupt the $25B osteoporosis market.","FDA-cleared for maxillofacial bone; streamlined path to clearance for full skeletal applications.","Thousands of successful patients treated with regenerative bone solutions using proven materials.","Clear exit strategy within 3 years, with potential acquisition by industry leaders.","Novel alternative to osteoporosis drugs with no systemic side effects—patients demand better.","Innovative specialty clinics will deliver localized treatment with scalable patient care models."]},"computed_metrics":{"total_amount_raised":383626,"total_investors":230,"team_size":3,"featured_investor_count":1,"faq_count":5,"recent_post_count":10},"quick_facts":[{"claim_id":"claim-fact-1","value":"Patented bone-regenerating technology ready to disrupt the $25B osteoporosis market.","citation":"https://wefunder.com/osnovum#claim-fact-1","observed_at":"2026-06-04T05:02:21Z","expires_at":"2026-06-11T05:02:21Z"},{"claim_id":"claim-fact-2","value":"FDA-cleared for maxillofacial bone; streamlined path to clearance for full skeletal applications.","citation":"https://wefunder.com/osnovum#claim-fact-2","observed_at":"2026-06-04T05:02:21Z","expires_at":"2026-06-11T05:02:21Z"},{"claim_id":"claim-fact-3","value":"Thousands of successful patients treated with regenerative bone solutions using proven materials.","citation":"https://wefunder.com/osnovum#claim-fact-3","observed_at":"2026-06-04T05:02:21Z","expires_at":"2026-06-11T05:02:21Z"},{"claim_id":"claim-fact-4","value":"Clear exit strategy within 3 years, with potential acquisition by industry leaders.","citation":"https://wefunder.com/osnovum#claim-fact-4","observed_at":"2026-06-04T05:02:21Z","expires_at":"2026-06-11T05:02:21Z"},{"claim_id":"claim-fact-5","value":"Novel alternative to osteoporosis drugs with no systemic side effects—patients demand better.","citation":"https://wefunder.com/osnovum#claim-fact-5","observed_at":"2026-06-04T05:02:21Z","expires_at":"2026-06-11T05:02:21Z"},{"claim_id":"claim-fact-6","value":"Innovative specialty clinics will deliver localized treatment with scalable patient care models.","citation":"https://wefunder.com/osnovum#claim-fact-6","observed_at":"2026-06-04T05:02:21Z","expires_at":"2026-06-11T05:02:21Z"}],"latest_fundraise":{"id":98100,"entity_id":"wefunder:fundraise:98100","state":"successful","offering_type":"4(a)(6)","structure":"equity","testing_the_waters":false,"can_invest_now":false,"funding_started_at":"2024-06-14T00:31:34Z","funding_closed_at":"2026-04-20T03:59:59Z"},"investor_memos":[],"team":[{"id":979904,"entity_id":"wefunder:company_role:979904","name":"Roslynn L Steiner","title":"CEO and President","role":"founder","profile_url":"https://wefunder.com/roslynn.l.steiner"},{"id":979882,"entity_id":"wefunder:company_role:979882","name":"Gregory Steiner","title":"Chief Science Officer","role":"founder","profile_url":"https://wefunder.com/gregorysteiner2"},{"id":979909,"entity_id":"wefunder:company_role:979909","name":"Daniel Vargas","title":"VP Marketing of SteinerBio and OsNovum","role":"employee","profile_url":"https://wefunder.com/nightbirdco"}],"featured_investors":[{"id":9220,"entity_id":"wefunder:company_investor_profile:9220","name":"Ron Ask","profile_url":"https://wefunder.com/ronask","endorsement_quote":"As an experienced dentist, we have been using the same bone graft materials in the jaws for over 15 years. I am excited to see this same technology used to regenerate bone from loss due to osteoporosis. This will greatly help to change the lives of millions of people. The current treatment for osteoporosis kills bone, OsNovum graft material builds strong bone and can be placed locally right were the bone loss occurs. This revolutionary treatment does not kill osteoclasts that are needed to create osteoblasts, which traditional treatments does."}],"relationships":[{"source_entity_id":"wefunder:company:63072","relation":"has_team_member","target_entity_id":"wefunder:user:916521","target_url":"https://wefunder.com/roslynn.l.steiner"},{"source_entity_id":"wefunder:company:63072","relation":"has_team_member","target_entity_id":"wefunder:user:913421","target_url":"https://wefunder.com/gregorysteiner2"},{"source_entity_id":"wefunder:company:63072","relation":"has_team_member","target_entity_id":"wefunder:user:919547","target_url":"https://wefunder.com/nightbirdco"},{"source_entity_id":"wefunder:company:63072","relation":"has_featured_investor","target_entity_id":"wefunder:user:1054570","target_url":"https://wefunder.com/ronask"},{"source_entity_id":"wefunder:company:63072","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:145483","target_url":"https://wefunder.com/feed/145483"},{"source_entity_id":"wefunder:company:63072","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:141412","target_url":"https://wefunder.com/feed/141412"},{"source_entity_id":"wefunder:company:63072","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:141390","target_url":"https://wefunder.com/feed/141390"},{"source_entity_id":"wefunder:company:63072","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:141360","target_url":"https://wefunder.com/feed/141360"},{"source_entity_id":"wefunder:company:63072","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:141221","target_url":"https://wefunder.com/feed/141221"},{"source_entity_id":"wefunder:company:63072","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:141121","target_url":"https://wefunder.com/feed/141121"},{"source_entity_id":"wefunder:company:63072","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:140658","target_url":"https://wefunder.com/feed/140658"},{"source_entity_id":"wefunder:company:63072","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:140153","target_url":"https://wefunder.com/feed/140153"},{"source_entity_id":"wefunder:company:63072","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:139905","target_url":"https://wefunder.com/feed/139905"},{"source_entity_id":"wefunder:company:63072","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:139697","target_url":"https://wefunder.com/feed/139697"},{"source_entity_id":"wefunder:company:63072","relation":"has_latest_fundraise","target_entity_id":"wefunder:fundraise:98100"}],"faq":[{"question":"Hi. I'm very interested but I have some questions if you don't mind: -How much will each application cost? -Will it be covered by insurance? -What are your revenue goals for the next 5 years? This is key for me as it will give me an idea of the company's potential and what kin...","answer":"Hello Leonardo All good questions. The cost will of course vary with the location and size of the lesion but we expect the charge approximately $5,000 per hip. Individual vertebrae would be less if multiple vertebrae are treated at once. OsNovum is classified as a bone graft and it will be covered as a bone graft. Virtually any insurance company would be happy to pay $5,000 to prevent a hip fracture. The plane is taxiing so I will complete my response latter.\u0026nbsp;"},{"question":"Cpñica okay, vacations from back surgery what can I be rewarded from medical malpractice","answer":"Cpnica? The vast majority of back surgeries are performed as a result of disk pathology. OsNovum has nothing to do with disk or cartilage pathology."},{"question":"I hope you can finish your answer before the early bird terms end, I need the revenue goals to make my decision.","answer":"Hello Leonardo Please read the following and get back to me. I just recently posted this to our investors. All the best,Financial Projections To: OsNovum Investors Here at OsNovum/SteinerBio we need to deal with facts. When treating a patient, you must put aside any bias or dogma and honestly critique how your patient responds to therapy. You cannot let what you want to happen cloud the reality of what is actually happening. This is ingrained in us and as a result we cannot look at business a..."},{"question":"Thanks for that. I was just hoping for your personal revenue goals, what numbers you are aiming to reach year by year. What's the margin on a $5,000 application? Can You disclose that?","answer":"Revenue goals We are wrapping up the FDA submission at this time and will hopefully submit in about 3 months. We could get approval in 6 months to a year and then we go to market. The costs associated with osteoporotic fractures is immense and that is related to our income. Let’s limit our discussion to about vertebral osteoporotic fractures to get a sense of the market and revenue stream. There are approximately 700,000 vertebral compression fractures per year in the US. There are currently ..."},{"question":"Hello Dr. Steiner Iam interested in investing and would like to know what distinguishes OsNovum from other treatments in the market such as Teriparatide(Forteo), Abaloparatide (Tymlos), Romosozumab (Evenity). In other words, what is your competitive advantage? Thanks","answer":"Hello SalehThe medications you list are systemic medications. They require continued use and have significant side effects. OsNovum in applied locally to the affected bone via a syringe. It is a one time application to regenerate the health of the bone. Our experience in the jaw indicates the effect is long lasting as we have not seen a decline is density over time. How long the effect will be in the rest of the skeleton is unknown at this time. OsNovum has no known side effects. All the best..."}],"recent_posts":[{"id":145483,"entity_id":"wefunder:feed_item:145483","title":"OsNovum Status","preview":"Hello OsNovum Owners,Our team at OsNovum has been quite busy. \u0026nbsp;We have closed funding, raising a total sum of $225,000. Wefunder will collect a small percentage of the total fee for helping us with the crowd funding project but ultimately, OsNovum will receive over $200,000 with the primary purpose of completing the FDA application and product clearance to market in the US. All proposed tests are now underway. Six tests are currently at NAMSA and are due to complete in approximately 2 mo...","published_at":"2021-06-02T16:25:29Z","canonical_url":"https://wefunder.com/feed/145483"},{"id":141412,"entity_id":"wefunder:feed_item:141412","title":"New Methods of Diagnosing Who Will Suffer a Bone Fracture","preview":"The current method of screening for risk of a fragility fracture is a dual-energy X-ray absorptiometry scan commonly referred to as DXA. The scan measures bone mineral density (BMD) and provides the patient and practitioner with a reading (T-score) that is used to determine if the patient has bone loss requiring treatment to prevent fracture:A patient is said to have normal bone when the T-score is higher than -1.0 SD.A patient is diagnosed with osteopenia when the T-score is between -1.0 and...","published_at":"2021-01-30T21:25:46Z","canonical_url":"https://wefunder.com/feed/141412"},{"id":141390,"entity_id":"wefunder:feed_item:141390","title":"Research findings: OsNovum reduces inflammation and stimulates bone growth.","preview":"The results are in and we are very proud to share the results of our first major FDA study for OsNovum. Our study for FDA clearance started in 2016 and we have now received the results. The study is a highly controlled study that requires registration with the FDA and the USDA. Over a thousand pages of documents have been complied to comply with FDA requirements. These studies are required to hire an independent outside quality control personnel to monitor all phases of the study. The FDA rev...","published_at":"2021-01-25T21:24:02Z","canonical_url":"https://wefunder.com/feed/141390"},{"id":141360,"entity_id":"wefunder:feed_item:141360","title":"Bone Repair vs Bone Regeneration","preview":"Most bone researchers study with bone repair. This is because orthopedic surgeons spend the majority of their time fixing damaged bones. The process of a long bone repair has very little to do with the process of bone regeneration. Our bones cannot fully heal themselves. Yes, broken bones can be made functional, but seldom is a repaired bone as good as new.At OsNovum we are only interested in bone regeneration. For regeneration to occur, the bone must be as good as new, or it is not regenerat...","published_at":"2021-01-23T20:48:10Z","canonical_url":"https://wefunder.com/feed/141360"},{"id":141221,"entity_id":"wefunder:feed_item:141221","title":"Factors Affecting Osteoporosis","preview":"Osteoporosis is like many of our chronic diseases of aging. Osteoporosis is associated with systemic inflammation. We know that an inflammatory environment stimulates osteoclasts to proliferate and remove bone and it stops osteoblasts from forming bone. However, this inflammation is not what we recognize as inflammation. There is no redness or swelling. The inflammation is characterized by circulating inflammatory molecules or inflammatory bacteria. You cannot look at the tissue to see the in...","published_at":"2021-01-19T21:28:01Z","canonical_url":"https://wefunder.com/feed/141221"},{"id":141121,"entity_id":"wefunder:feed_item:141121","title":"OsNovum nearing 150K in funding.","preview":"OsNovum has reached a milestone that will allow us to complete our submission and clearance with the FDA. This was our primary goal in selling shares of OsNovum and we thank all of those who have invested. We have been live on Wefunder for approximately 1 month and have 3 weeks left to raise additional capital. Our plan is to complete our submission and clearance for OsNovum and when we have acquired clearance, the value of your OsNovum shares will be significantly enhanced and our ability to...","published_at":"2021-01-16T21:03:11Z","canonical_url":"https://wefunder.com/feed/141121"},{"id":140658,"entity_id":"wefunder:feed_item:140658","title":"Osteoporosis drugs- effectiveness and side effects","preview":"OsNovum was developed to fill a need not realized by the available osteoporosis drugs. The use antiresorptive (bone removal) osteoporosis medications have declined in use as osteoporosis diagnosis has increased. Questionable effectiveness including serious side effects have pushed many patients away from using these medications irrespective of their serious osteoporotic condition. The main class of antiresorptive osteoporosis drugs is the bisphosphonates. These drugs gained notoriety due to t...","published_at":"2021-01-01T23:03:17Z","canonical_url":"https://wefunder.com/feed/140658"},{"id":140153,"entity_id":"wefunder:feed_item:140153","title":"OsNovum testing progress","preview":"We have been making good progress with our testing for FDA submission. We have just received our histopathology report that looks at inflammation produced by the bone graft at different time points. We compared a control (no graft) to a cadaver bone graft and our graft. The findings are in, but the final statistical analysis is not yet complete, but it looks very good for our product. For the second component of our FDA submission, we are contracting with a major biomedical testing company to...","published_at":"2020-12-24T20:20:49Z","canonical_url":"https://wefunder.com/feed/140153"},{"id":139905,"entity_id":"wefunder:feed_item:139905","preview":"OsNovum Owners update: FDA testingThe FDA does not have rules to follow when submitting a material for clearance to market a product. The FDA only has guidelines and it is up to the company to convince the FDA that the tests performed on the product are sufficient to determine that product is safe and effective. In addition to no rules, what is accepted will be determined by the attitude of the office who reviews the submission. When you submit to the FDA the officer will reply with a list of...","published_at":"2020-12-15T00:10:30Z","canonical_url":"https://wefunder.com/feed/139905"},{"id":139697,"entity_id":"wefunder:feed_item:139697","preview":"I have just responded to an inquiry about projected revenue for OsNovum. I used percutaneous vertebroplasty as an example of how common collapsed vertebra are and the cost associated with treatment. I used these figures to give an idea of how OsNovum can be used for this problem and how much revenue can be generated. Percutaneous vertebroplasty injects plastic into the vertebrae to support it and stabilize it. The plastic never goes away. The type of material used in percutaneous vertebroplas...","published_at":"2020-12-08T22:38:22Z","canonical_url":"https://wefunder.com/feed/139697"}],"provenance":{"source":"wefunder_public_company_profile","as_of":"2026-06-04T15:19:25Z","claims":{"total_amount_raised":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-04T05:02:21Z","as_of":"2026-06-04T15:19:25Z","confidence":"high"},"total_investors":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-04T05:02:21Z","as_of":"2026-06-04T15:19:25Z","confidence":"high"},"active_raise_states":{"source":"Fundraise.visible(nil, nil)","last_verified_at":"2026-06-03T21:32:39Z","as_of":"2026-06-04T15:19:25Z","confidence":"high"},"latest_fundraise_state":{"source":"Fundraise.visible(nil, nil).order(funding_started_at)","last_verified_at":"2026-06-03T21:32:39Z","as_of":"2026-06-04T15:19:25Z","confidence":"medium"}}}}}}